Polarean Imaging PLC Block Listing Six Monthly Return (2883H)
27 July 2023 - 4:00PM
UK Regulatory
TIDMPOLX
RNS Number : 2883H
Polarean Imaging PLC
27 July 2023
Polarean Imaging Plc
("Polarean" or the "Company")
Block Listing Six Monthly Return
Polarean Imaging plc (AIM: POLX), a commercial-stage medical
device leader in advanced MRI scanning of the lungs, today makes
the following notification pursuant to Schedule Six of the AIM
Rules for Companies regarding its existing block admission
arrangements:
Name of applicant: Polarean Imaging Plc
Name of scheme: Polarean Share Option Plan
-------------------------------------------------
Number and class of securities originally admitted: 8,000,000 ordinary shares of GBP0.00037 each
-------------------------------------------------
Date of admission: 29 July 2021
-------------------------------------------------
Period of return: From: 26 January 2023 To: 26 July 2023
------------------------ ---------------------- ------ -----------------
Balance of unallotted securities under scheme(s) from previous
return: 4,025,657
-------------------------------------------------
Plus: The amount by which the block scheme(s) has been increased
since the date of the last
return (if any increase has been applied for): 0
-------------------------------------------------
Less: Number of securities issued/allotted under scheme(s)
during period (see LR3.5.7G): 852,822
-------------------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end
of period: 3,172,835
-------------------------------------------------
Total number of securities in issue at the end of the period 213,900,331
-------------------------------------------------
Name of contact: Charles F. Osborne, Jr., Chief Financial Officer
Telephone number of contact: + 44 (0)20 7933 8780 or polarean@walbrookpr.com
-------------------------------------------------
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Christopher von Jako, Chief Executive Via Walbrook PR
Officer
Kenneth West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw
(Healthcare
Investment Banking)
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical imaging
technology companies operating in the high-resolution medical
imaging space. Polarean aspires to revolutionise pulmonary medicine
by bringing the power and safety of MRI to the respiratory
healthcare community in need of new solutions to evaluate lung
ventilation, diagnose disease, characterise disease progression,
and monitor response to treatment. By researching, developing, and
commercialising novel imaging solutions with a non-invasive and
radiation-free functional imaging platform. Polarean's vision is to
help address the global unmet medical needs of more than 500
million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarisation
science and has successfully developed the first and only
hyperpolarised MRI contrast agent to be approved in the United
States. The company also commercialises systems (such as the HPX
hyperpolarisation system), accessories (such as Xe-specific chest
coils and phantoms) and FDA-cleared post-processing software (to
support ventilation defect analysis), to support fully integrated
modern respiratory imaging operations.
PLC-RNS-2314
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRNKABBDBKDKOB
(END) Dow Jones Newswires
July 27, 2023 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024